Background: Assessment of muscle wasting in COPD is relevant as it is independently associated with metabolic and functional consequences and even survival. Muscle wasting can be approached by assessing fat free mass (FFM), but it is already demonstrated that FFM measured by bio-electrical impedance analysis (BIA) underestimates FFM measured by dual energy X-ray absorptiometry (FFM DExA ) in a relatively small COPD group. Objective: To evaluated critical points for defining muscle wasting in a large cohort of moderate to severe COPD patients and with DEXA scan as reference. Design: FFM by BIA was compared with FFM DExA in 1087 COPD patients (641_, FEV 1 : 44.8 AE 17.5%pred). In a subgroup (n Z 422), FFM DExA was predicted by multivariate analysis and a new formula to calculate FFM by BIA was developed. The new formula was compared with FFM DExA in the remaining subgroup (n Z 665). 
Introduction
Besides the respiratory disorder, chronic obstructive pulmonary disease (COPD) is nowadays generally accepted as a systemic disease. 1 Decreased skeletal muscle mass is one of the most investigated extra-pulmonary features in COPD. Indeed, an abnormal low muscle mass is present in about 40% of the patients with moderate to severe COPD entering pulmonary rehabilitation. 2 A comparable proportion of muscle wasting of about 30% was found in a large group of COPD outpatients with GOLD stages 2 and 3, independent of patients' body weight. 3 Muscle wasting is negatively associated with exercise capacity 4 and quality of life 5 in COPD. Moreover, mortality rate is higher in COPD patients with muscle wasting than in those patients with preserved muscle mass, independent of the body weight. 6 Therefore, an accurate diagnosis of muscle wasting in COPD is clinically relevant. Indeed, clinical experience indicates that assessment of body composition is increasingly embedded in the clinical management of patients with COPD. Nevertheless, the prevalence of muscle wasting is largely dependent on the used technique. The dual energy X-ray absorptiometry (DEXA) scan has been shown to be accurate for the measurement for the lean body mass in healthy subjects 7 and in patients with COPD. 8, 9 However, this technique is rather expensive and therefore not easy to use in clinical routine. Single-frequency bio-electrical impedance analysis (BIA) is also recognized as a reliable and useful tool to assess fat free mass (FFM, a marker for skeletal muscle mass) in clinical practice. 10 However, the FFM derived from this technique is dependent on the formula used. Various general and patient specific formulas are circulating, and some of them are age-dependent while others are not. Research has shown a standard underestimation of the FFM assessed by BIA when compared to the FFM assessed by DEXA scan in patients with COPD. 11, 12 So, the current COPD specific formula to estimate FFM using the BIA does not seem to be accurate enough when compared with DEXA measures. Moreover, the formula has been based on a group of only 117 COPD patients in total. 11 Therefore, there seems to be a clear rationale to evaluate the formula to estimate FFM by BIA in a large cohort of COPD patients. Finally, the prevalence of muscle wasting is dependent on the used cut offs. To date, various COPD specific cut offs are circulating, 3 but a proof of principle is warranted.
In the present study, FFM is measured by the BIA and compared with the FFM measured by DEXA (FFM DExA ) in a large cohort of clinically stable patients with moderate to severe COPD entering pulmonary rehabilitation. The DEXA scan is used as the reference method for assessing skeletal muscle mass. Using multivariate stepwise regression analysis, FFM DExA is predicted in a subgroup of the patients by using the impedance received from the BIA. The new formula obtained from the regression equation was evaluated in the remaining group and in various age groups. In addition, the proportion of muscle wasting was determined in our sample using the different techniques and using various cut-offs widely used to define muscle wasting in COPD 3 and healthy elderly. 
Body composition
Body height was measured to the nearest 0.1 cm. Body composition was assessed by using two different techniques in the post-absorptive state and within 2 days. For the BIA analysis (Bodystat â ), body weight was assessed by using an electronic beam scale with digital readout to the nearest 0.1 kg after emptying the bladder and with the subjects standing barefoot and wearing light indoor clothing. Whole body impedance (expressed in U) was measured in each subject by lying on the bed and with separated legs. For the calculation of the FFM, the patient and sex-specific formula of Steiner et 
Statistical analyses
Data were normally distributed and reported as mean AE standard deviation (SD). Sex-differences were tested using an unpaired Student's t-test. The group was randomly split into two groups with comparable general characteristics (Table 1 ). In the first group of 422 subjects, stepwise multiple regression analysis with FFM DExA as dependent variable and age, sex, height, weight and height 2 /(impedance from the BIA) as independent variables is performed. From this, a new regression formula was created (FFM Form 
Results
Characteristics of the patients are shown in Table 2 . The patients were characterized by moderate to severe COPD. The women were younger than the men and they had lower weight, BMI and bone mineral content, but the same degree of lung function impairment.
The coefficient of determination between mean FFM Steiner and FFM DExA was 0.88 and comparable between men and women (R 2 Z 0.80 vs. 0.74, respectively; both p < 0.01, Fig. 1A) . Limits of agreement between the /impedance showed a prediction of 90% ( Table 3) . From this, a sex-specific formula to calculate FFM by the impedance in our COPD population was created: FFM Form Fig. 2A 11 Segal et al. 17 ) and healthy elderly (Deurenberg et al., 16 Dey et al. 15 ). In men (Fig. 3A) , FFM DExA decreased with increasing age (p < 0.01), while in women (Fig. 3B) , FFM DExA was not age-dependent. As expected, the new formula was closely linked to the FFM DExA , as did the formula by Dey. The formulas by Deurenberg and Steiner significantly underestimated the FFM when compared to the FFM DExA (p < 0.01) while the formula by Segal significantly overestimated the FFM DExA (p < 0.01).
In Fig. 4 , the percentage of patients with muscle wasting calculated by the cut offs of Schols et al. 2 (A), Vestbo et al. 3 (B) and Coin et al. 7 (C) is shown. FFMI is derived from DEXA scan and BIA after which FFM is calculated by the formula of Steiner et al. and the new formula. In both in men and in women, the proportion of muscle wasting was higher using the FFM Steiner vs. the FFM DExA and FFM Form (both p < 0.01). Comparing the proportion muscle wasting derived from the FFM DExA with the FFM Form , the difference was statistically 
Discussion
The present study evaluated critical points in the assessment of muscle wasting in a large group of moderate to severe clinically stable patients with COPD. An underestimation of the FFM measured by BIA and calculated by Steiner's formula is found when compared to the FFM measured by DEXA. As this underestimation is already previously shown, 11 the authors approached to create a new formula to calculate FFM by BIA by using the stepwise multivariate regression. From this, a new COPD specific formula was formed. The proportion of muscle wasting is largely dependent on the used cut-offs, especially in men. The findings of the present study emphasize the importance to accurately bare in mind these criteria to establish muscle wasting before implementing it in the clinical practice.
It has previously been shown that muscle wasting is associated with metabolic 18 and functional consequences. 19 Assessment of body mass index alone for screening on body composition in patients with COPD seems not accurate as there is a subgroup of patients with normal BMI and muscle wasting. 2 Therefore, defining muscle wasting in the screening and the treatment of COPD patients is clinically relevant. The present study shows that the accuracy of this definition depends on various factors like the technique used to measure FFM and the cut-offs on which muscle wasting is based. Both factors will be discussed in the following section.
Various studies evaluated the proportion of muscle mass in patients with COPD by using different techniques and with the DEXA scan as the reference method. 11, 12 In both studies, there is great discrepancy of the limits of agreement when the BIA and the anthropometric methods were compared with the DEXA scan. Conclusive, the proportion Significant different from FFM DExA : **P < 0.01. muscle wasting in a COPD population differs depending on the technique used. Even, besides intra-technical differences (various soft wares for DEXA scan, different BIA devices), inter-technical differences are even greater. In the study by Steiner et al., 11 the prevalence of muscle wasting was 36 and 42% in men and 72 and 59% in women when respectively the DEXA and BIA was used. In the more recent study by Lerario et al., 12 the changes between the DEXA scan and BIA were smaller, respectively 25 and 28%. In both studies, the cut-offs of Schols et al. were used to define muscle wasting. 2 Moreover, the proportion of muscle wasting was higher in the study by Steiner et al. 11 compared to the study by Lerario et al., 12 likely partly because the patients included in the study by Steiner et al. had more severe COPD. Both studies concluded that BIA underestimated FFM when compared with DEXA. In the present study, the proportion of muscle wasting according to the cut-offs of Schols et al. was about 15 and 37% for men and about 45 and 59% for women for respectively DEXA and BIA. The discrepancy between methods may have great impact as nutritional supplements are often prescribed in clinical research, 20, 21 but also in patient's health care. 22 In this view, the new formula in the present study is proficient to minimize the discrepancy of the FFM, and particularly the FFMI that existed between the DEXA and the BIA method. However, as relatively great limits of agreements remain with the new formula, the DEXA device still is more profound to screen for muscle wasting, as confirmed in a recent published paper. 9 If the BIA method is only at hand, the new formula may give a better approach to estimate skeletal muscle mass than previous COPD specific formulas.
Recently, three studies summarized the prevalence of muscle wasting in cohorts of COPD outpatients 3, 23, 24 ( Table 4) . In all these studies, BIA was used to calculate FFM, and the prevalence of muscle wasting was defined by the cut-offs of Schols et al. The formulas of Segal et al. 3, 23, 24 and Steiner et al. 3, 23, 24 were used to calculated FFM. The proportion of muscle wasting in the present study is higher when compared to the other studies. This can at least partly be explained by the fact that we studied complex COPD patients admitted for pulmonary rehabilitation. Until now, there is no study that appraises muscle wasting by using the DEXA scan in a large group of COPD patients.
The findings of the present study emphasis the importance of the cut-offs for defining muscle wasting. The cutoffs of Schols et 7 Together with the fact that the proportion of muscle wasting based on the cut-off of Vestbo et al. in men move toward the proportion in women (see Fig. 4 ), the authors conclude that the cut-offs of Vestbo et al. approach most optimal the cutoffs for defining muscle wasting. Based on these cut offs, the prevalence of muscle wasting in the present cohort of moderate to severe patients with COPD admitted for pulmonary rehabilitation is about 30% for both men and women. Nevertheless, the present authors believe that future epidemiologic research has to further evaluate the criteria for diagnosing muscle wasting in chronically ill patients.
To further evaluate the new formula, the authors compared FFM DExA and FFM Form with different formulas in various age categories. In male but not in female COPD patients, FFM DExA decreased with increasing age. These findings are in line with findings in healthy elderly, were FFM assessed by BIA decreased from 35 to 55 y in men but remained stable in women. 25 Another study reported that the FFM decreased after 60 y in men, and to a lower extent also in women. 26 These data imply that, at least the pattern, of the age-dependant progress remains comparable in patients with COPD and healthy subjects. Moreover as expected, the new formula was closely linked to the FFM DExA , as did the formula by Dey et al. 15 
Limitations of the study
The authors would like to address various limitation of the study. Firstly, the DEXA scan was used as the reference method for the FFM. The authors are aware that the DEXA scan is not the golden standard for body compositional measurement, like double labeled water technique or magnetic resonance imaging. 27 There are few studies determining the accuracy of the DEXA scan for muscle mass assessment. These studies concluded that DEXA scan showed better precision compared to bedside methods like BIA. 28 Indeed, DEXA has been shown as a useful technique to measure FFM in patients with COPD. 8 Furthermore, FFM DExA was assessed by summing up lean mass and bone mineral content. It has been shown that bone mineral content is lower in patients with COPD compared to healthy controls, 29 which could contribute to the lower FFM DExA compared to the FFM BIA . Nevertheless, the contribution of the bone mineral content to the FFM is relatively small and is therefore unlikely to influence our results. Secondly, patients with clinically diagnosed edema were excluded from the study, but it cannot be concluded that all patients were free of any level of edema. Especially in patients with In all studies, COPD outpatients were included, BIA was used to estimate fat free mass, and the prevalence of muscle wasting was defined by the criteria of Schols et al. extreme low FFM, the extracellular water compartment can be increased. 4 In these patients with non-visual levels of edema, the body composition data are not reliable. This hassle counts for both the BIA and the DEXA technique.
To summarize, the results of the present study show that both the technique to determine FFM and the cut-offs to define an abnormal low FFMI are of importance to accurately diagnose muscle wasting in patients with COPD. The authors concluded that the formula derived in the present study can be used for the FFM assessment by using BIA in clinically stable patients with COPD.
